These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258 [TBL] [Abstract][Full Text] [Related]
29. Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B. Ma MT; Meszaros LK; Paterson BM; Berry DJ; Cooper MS; Ma Y; Hider RC; Blower PJ Dalton Trans; 2015 Mar; 44(11):4884-900. PubMed ID: 25351250 [TBL] [Abstract][Full Text] [Related]
30. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. Zeglis BM; Lewis JS J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741890 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793 [TBL] [Abstract][Full Text] [Related]
33. [ Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310 [TBL] [Abstract][Full Text] [Related]
34. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600 [TBL] [Abstract][Full Text] [Related]
35. Bioorthogonal Fluorophore Linked DFO-Technology Enabling Facile Chelator Quantification and Multimodal Imaging of Antibodies. Meimetis LG; Boros E; Carlson JC; Ran C; Caravan P; Weissleder R Bioconjug Chem; 2016 Jan; 27(1):257-63. PubMed ID: 26684717 [TBL] [Abstract][Full Text] [Related]
36. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. Deri MA; Ponnala S; Kozlowski P; Burton-Pye BP; Cicek HT; Hu C; Lewis JS; Francesconi LC Bioconjug Chem; 2015 Dec; 26(12):2579-91. PubMed ID: 26550847 [TBL] [Abstract][Full Text] [Related]
37. Development of a Specifically Labeled Zheng M; Liu Q; Zhang H; Wang Y; Zhang K; Mu H; Fu F; Zhang X; Wang Y; Miao L Mol Pharm; 2024 Oct; 21(10):5205-5216. PubMed ID: 39322604 [TBL] [Abstract][Full Text] [Related]
38. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts. Cheal SM; Ruan S; Veach DR; Longo VA; Punzalan BJ; Wu J; Fung EK; Kelly MP; Kirshner JR; Giurleo JT; Ehrlich G; Han AQ; Thurston G; Olson WC; Zanzonico PB; Larson SM; Carrasquillo JA Mol Pharm; 2018 Jun; 15(6):2133-2141. PubMed ID: 29684277 [TBL] [Abstract][Full Text] [Related]
39. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Wang S; Li J; Hua J; Su Y; Beckford-Vera DR; Zhao W; Jayaraman M; Huynh TL; Zhao N; Wang YH; Huang Y; Qin F; Shen S; Gioeli D; Dreicer R; Sriram R; Egusa EA; Chou J; Feng FY; Aggarwal R; Evans MJ; Seo Y; Liu B; Flavell RR; He J Clin Cancer Res; 2021 Mar; 27(5):1305-1315. PubMed ID: 33293372 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates. Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]